Health Canada Approves VYVGART SC as First Novel CIDP Treatment in Three Decades
核心洞察
Health Canada has authorized VYVGART SC (搜索) (efgartigimod alfa injection) as the first innovative treatment for chronic inflammatory demyelinating polyneuropathy (搜索) (CIDP (搜索)) in more than 30 years.
The subcutaneous injection represents the first and only neonatal Fc receptor (搜索) blocker approved for CIDP (搜索) treatment, offering patients flexible self-administration options.
The approval is based on the ADHERE study, which demonstrated a 61% reduction in relapse risk and showed 69% of patients experienced clinical improvement.
argenx SE (搜索) announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC (搜索) (efgartigimod alfa injection) as a monotherapy for treating adult patients with active chronic inflammatory demyelinating polyneuropathy (搜索) (CIDP (搜索)). This milestone marks the first innovative treatment for CIDP in more than 30 years and establishes VYVGART SC as the first and only neonatal Fc receptor (搜索) (FcRn (搜索)) blocker authorized in Canada for this rare autoimmune condition.
Breakthrough Treatment for Rare Neurological Disorder
VYVGART SC (搜索) is authorized for CIDP (搜索) as a once-weekly 20-30 second subcutaneous injection delivered via prefilled syringe. The treatment offers patients unprecedented flexibility, allowing self-administration or caregiver assistance at home, while mobile, or in clinical settings. This represents a significant advancement for patients who have faced limited therapeutic options for decades.
"Many Canadian CIDP (搜索) patients face progressive weakness, numbness and disability, and have had limited treatment options for far too long," said Hans Katzberg, M.D., Neuromuscular Neurologist and Division Head of Neurology at University Health Network Toronto. "The authorization of VYVGART SC (搜索) marks a significant advance, potentially offering an important new way to effectively treat this challenging disease and improve outcomes while reducing the burden on patients."
Clinical Evidence from Landmark Trial
The Health Canada authorization is supported by positive results from the ADHERE study, the largest clinical trial conducted to date in CIDP (搜索). The multi-center, randomized, double-blind, placebo-controlled trial enrolled 322 adult patients with CIDP and consisted of an open-label Stage A followed by a randomized, placebo-controlled Stage B.
In the study, 69% (221/322) of patients treated with VYVGART SC (搜索), regardless of prior treatment, demonstrated evidence of clinical improvement, including enhanced mobility, function, and strength. The study met its primary endpoint (p<0.0001), showing a 61% reduction (HR: 0.39, 95% CI: 0.25; 0.61) in the risk of relapse versus placebo.
The safety results were generally consistent with the known safety profile of VYVGART in previous clinical studies and real-world use. Nearly all (99%) participants chose to participate in the ADHERE+ open-label extension study, indicating strong patient acceptance of the treatment.
Addressing Significant Unmet Medical Need
CIDP (搜索) is a rare, debilitating and often progressive autoimmune disorder of the peripheral nervous system. Patients experience a range of disabling mobility and sensory issues, including difficulty standing from a seated position, pain, fatigue, and frequent tripping or falling. As the disease progresses, patients may require wheelchair use and become unable to work or participate in daily activities.
Globally, 85% of patients require ongoing treatment and nearly 88% of treated patients continue to experience residual impairment and disability. According to feedback from patients and clinicians provided to the Canadian Drug Agency and the National Institute for Excellence in Health and Social Services, 30-40% of patients may not be adequately treated with conventional therapies.
Impact on Healthcare System
Currently available CIDP (搜索) treatments include intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg), with CIDP patients accounting for approximately 20% of IVIg/SCIg use in Canada. Demand for human-derived blood products continues to grow at 7-8% annually in Canada, underscoring the importance of new, targeted treatment alternatives such as VYVGART SC (搜索) to help reduce demand and support future supply of blood products.
"There remains a significant unmet need among Canadians living with CIDP (搜索), who face progressive weakness, numbness and disability," said François Jacques, M.D., Neurologist at Clinique Neuro-Outaouais. "The authorization of VYVGART SC (搜索) brings a novel, targeted therapy that offers a new way of treating patients, with meaningful improvements in strength and function."
Patient Community Response
Patient advocacy organizations have welcomed the authorization as a significant step forward. "Health Canada's authorization of VYVGART SC (搜索) for CIDP (搜索) is an encouraging and important step forward for Canadians living with this rare condition," said Stacey Lintern, Chief Executive Officer of Muscular Dystrophy Canada. "The availability of a subcutaneous option represents meaningful progress in improving both access and patient experience."
Donna Hartlen, Executive Director of the GBS/CIDP (搜索) Foundation of Canada, emphasized the broader impact: "Patients living with CIDP have varying disabilities that can profoundly affect their social lives and careers. This authorization of VYVGART SC (搜索) by Health Canada is the first step toward offering more treatment options and fair access for individuals living with CIDP."
Mechanism of Action
VYVGART SC (搜索) is a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE drug delivery technology, to facilitate subcutaneous injection delivery of biologics. In binding to the neonatal Fc receptor (搜索) (FcRn (搜索)), VYVGART results in the reduction of circulating IgG autoantibodies (搜索), which play a key role in the damage to peripheral nerves in CIDP (搜索).